This disorder is associated with an increased risk for mortality, cardiovascular events, hospitalizations, and intensive care unit admissions [2], and is more common in individuals with chronic kidney disease (CKD) and diabetes treated with guideline-directed medical therapy [3]
As per research, it plays a crucial role in protecting cells from damage caused by free radicals and unstable molecules that can contribute to aging and various diseases
Pfizer, YaoPharma Sign Global Deal for Oral GLP-1 Candidate Pfizer has signed an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, to advance the development of YP05002, an oral GLP-1 receptor agonist in Phase 1 studies for chronic weight management
European Respiratory Society
But, its essential to follow the healthcare providers instructions